Drug Microarray Patch
Technical Development
WCC has pioneered an advanced microneedle platform geared toward the efficient production of Microarray Patches (MAPs). WCC’s platform has laid a robust foundation that can accommodate various types of drugs through advanced formulation process to accomodate drug such as insulin, pain relief, hormones, and more, all within the framework of MAPs. As innovators in the field of MAPs, WCC has captured the attention of several pharmaceutical companies’ interest by the prospect of incorporating their own drugs into WCC’s MAPs.
Applicaiton
Diabetes, HGH, Antiemetic, Pain-relief
Advantages
1. Dosage can be precisely controlled
2. Exclusive controlled release mechanism
3. Feasible to submit 505(b)2 regulatory pathway
Cooperation
ODM/RD or others
WCC’s Pain-relief Patch
Currently, WCC is in the process of developing a pain-relief patch that utilize microneedle technology. Unlike the currently available dosage forms on the market, microneedles are expected to provide a faster onset time compared to topical or transdermal applications and offer a longer duration of relief. Moreover, WCC’s microneedles are designed to be painless and ensure precise drug delivery to the affected area.
